Navigating chemotherapy-induced thrombocytopenia: Insights from the RECITE Phase III trial
Chemotherapy-induced thrombocytopenia (CIT) often forces clinicians to delay or reduce cancer treatment. Recently reported data from the Phase…
Romiplostim shows promise in treating chemotherapy-induced thrombocytopenia
Original story from Mass General Brigham The Phase III RECITE trial has shown that romiplostim prevents serious side…